Quantum biopharma announces joint clinical study with massachusetts general hospital scientists to validate a novel positron emission tomography (pet) imaging technique to monitor demyelination in multiple sclerosis

Toronto, april 01, 2025 (globe newswire) -- quantum biopharma ltd. (nasdaq: qntm) (cse: qntm) (fra: 0k91) “quantum biopharma” or the “company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on march 31, 2025 it has entered into a joint clinical study with massachusetts general hospital (mgh) scientists to validate a novel positron emission tomography (pet) imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis (ms).
QNTM Ratings Summary
QNTM Quant Ranking